[엠디데일리] The Ministry of Health and Welfare (Minister Kwon Deok-cheol) announced that the total number of global technology exports in 2020 by domestic pharmaceutical and bio companies supported by the Ministry of Health and Welfare and the Korea Health Industry Promotion Agency (Cho-il Kim, acting as the president) totaled 6 cases, worth about 6.8 trillion won.
Ministry of Welfare and Welfare R&DMajor technology export performance of the business(’20)
|
year month |
Company name |
Product (substance) name |
Kinds |
Technology transfer amount (advance payment) |
Technology transfer company |
Government support project |
|
‘20.06 |
Alteogen |
ALT-B4 Platform technology |
Source technology for hypodermic injection |
KRW 4 trillion KRW 700 billion (KRW 19.2 billion) |
Top 10 global pharmaceutical companies |
Pan-Ministry Full-cycle new drug development project* |
|
‘20.08 |
Yuhan Corporation |
YH12852 |
Functional Gastrointestinal disease treatment |
KRW 4872 billion (2.4 billion won) |
U.S./Processor Pharmasutical |
Advanced medical technology development business |
|
‘20.10 |
SK Biopharm |
Senobamate |
Epilepsy treatment |
KRW 5788 billion (54.5 billion won) |
Japan/Ono Pharmaceutical Industry |
Pan-Ministry Full-cycle new drug development project* |
|
‘20.10 |
Voronoi |
VRN07 |
Candidate drug for mutant non-small cell cancer and solid cancer treatment |
KRW 720 billion (14.8 billion won) |
US/Oric |
Advanced medical technology development business |
|
‘20.12 |
Legochem Bioscience |
LCB67 |
Anticancer drug ADC* candidate LCB67 *Antibody-Drug Conjugate |
KRW 325.5 billion (KRW 10.5 billion) |
USA/Pixis On Cology |
Advanced medical technology development business |
<3개 부처(보건복지부, 과학기술정보통신부, 산업통상자원부) 공동지원>
This achievement is equivalent to 67% of the total amount of technology export contracts for domestic pharmaceutical and bio companies in 2020 announced in December last year by the Pharmaceutical Bio Association (Chairman Hee-mok Won).Alteogen, Borough Bio venture companies such as Noi and Legochem Bioscience showed strong strength at 84% of the total.
In particular, the achievements of open innovation (open innovation) in which global pharmaceutical companies receive technology transfer and develop original technologies and new drug candidates developed by bio-venture companies are the main achievements.
Alteogen’s ALT-B4 is a human recombinant hyaluronic acid degrading enzyme that can replace intravenous antibody and protein drug formulations with subcutaneous drugs.
It was developed through Alteogen’s self-developed subcutaneous injection formulation modification platform technology (Hybrozyme), and additional technology exports are expected in the future through the use of such platform technology.
Yuhan’s YH12852 is a gastrointestinal tract disease treatment. After successfully completing preclinical toxicity and phase 1 clinical trials in Korea, the technology is transferred to the United States, and a phase 2 clinical trial is planned in the United States in 2021.
SK Biopharm’s Cenovamate is Korea’s first epilepsy treatment, and it has independently carried out the entire process from discovery of candidate substances to global clinical development and marketing approval.
In recent years, it is expected to achieve Korea’s first global blockbuster drug (sales of more than KRW 1 trillion), with technology transfer performance of up to KRW 5788 billion (down payment of 54.9 billion KRW, commercialization achievement technology fee of 524.3 billion KRW and royalties) in Japan.
Voronoi’s VRN07 is a new drug candidate that can selectively act on non-small cell lung cancer caused by gene (Exon 20 insertion) mutation, and is expected to be an effective treatment method for mutant non-small cell lung cancer and solid cancer patients suffering from general chemotherapy. It is expected.
LCB67 of Legochem Bioscience (hereinafter referred to as Legochem) is a new drug candidate that selectively acts on cell lung cancer, liver cancer, and various solid cancers.
It was developed through self-developed next-generation platform technology ADC (Antibody-Drug Conjugate), and succeeded in global technology transfer of a total of 4 candidate substances using next-generation platform technology including LCB67 only last year to the United States, China, and Europe. did.
Hyeon Soo-yop, a high-tech medical support officer at the Ministry of Welfare, said, “Because of the challenging R&D and bold investments of private companies, we were able to achieve the highest technology export performance ever. The support project is positioning itself as an innovation partner that shares the risk of developing new drugs.”
The Ministry of Health and Welfare said, “From 2021, we plan to further strengthen full-cycle support through national R&D projects by removing partitions between ministries from basic research on new drug development to commercialization.”
Reporter Lee Young-bok 48yblee
<저작권자 © 엠디저널, 무단 전재 및 재배포 금지>